ORASURE TECHNOLOGIES, INC
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $167.1M | $128.2M | $119.7M | $106.1M | $97.6M | $90.7M | $83.2M | $74.6M |
| Diagnostics | $109.2M | $89.2M | $86.3M | $78.8M | $73.4M | $73.5M | $79.2M | $74.6M |
| Molecular Solutions | $57.9M | $39.0M | $33.3M | $27.3M | $24.2M | $17.2M | $4.0M | $0 |
| Cost of Revenue | $68.1M | $40.2M | $39.4M | $39.8M | $40.4M | $32.2M | $30.2M | $27.7M |
| Gross Profit | $99.0M | $88.0M | $80.3M | $66.6M | $58.6M | $55.6M | $51.7M | $47.4M |
| Gross Margin | 59.2% | 68.7% | 67.1% | 62.8% | 60.0% | 61.3% | 62.2% | 63.5% |
| Operating Expenses | ||||||||
| Research & Development | $13.4M | $9.8M | $11.7M | $12.1M | $10.9M | $12.4M | $18.4M | $13.2M |
| SG&A Expense | $29.3M | $28.4M | $25.5M | $23.8M | $21.7M | $22.3M | $20.3M | $16.8M |
| Operating Income | $40.2M | $20.3M | $8.1M | $-4.8M | $-12.2M | $-16.3M | $-9.4M | $-3.4M |
| Operating Margin | 24.1% | 15.8% | 6.7% | -4.5% | -12.5% | -17.9% | -11.3% | -4.5% |
| Interest Expense | — | — | — | — | — | $172.0K | $316.0K | $316.0K |
| Pretax Income | $41.0M | $20.3M | $8.8M | $-4.3M | $-12.0M | $-16.5M | $-9.7M | $-3.5M |
| Income Tax Expense | $10.1M | $603.0K | $665.0K | $343.0K | $-772.0K | $-1.4M | $-869.0K | — |
| Net Income | $30.9M | $19.7M | $8.2M | $-4.6M | $-11.2M | $-15.1M | $-8.8M | $-3.5M |
| Net Margin | 18.5% | 15.4% | 6.8% | -4.3% | -11.5% | -16.7% | -10.6% | -4.7% |
| EPS (Basic) | $0.52 | $0.35 | $0.14 | $-0.08 | $-0.20 | $-0.29 | $-0.19 | $-0.08 |
| EPS (Diluted) | $0.51 | $0.35 | $0.14 | $-0.08 | $-0.20 | $-0.29 | $-0.19 | $-0.08 |
| Shares Outstanding (Basic) | 59.1M | 55.6M | 56.4M | 55.9M | 55.6M | 51.5M | 46.9M | 46.2M |
| Shares Outstanding (Diluted) | 61.0M | 56.5M | 56.8M | 55.9M | 55.6M | 51.5M | 46.9M | 46.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |